Compare Cassava Sciences Inc (FLNA) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Valero Energy Corporation — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Valero Energy Corporation trades at $442.5 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 3243.1× Cassava Sciences Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Valero Energy Corporation for 56 Days on average.
| FLNA | VLO | |
|---|---|---|
Market Cap | $39.40M | $127.78B |
Volume | 759,018 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $4.64 | $443.80 |
52-Week Low | $0.68 | $156.39 |
Typical Hold Time | 37 Days | 56 Days |
Enterprise Value | -$43.28M | $131.26B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Valero Energy (VLO) trades at $424.10, up 1.16% today, near its 52-week high. The stock exhibits bullish technical signals with strong moving average alignment and has beaten earnings estimates for three consecutive quarters. Revenue declined to $122.69 billion in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a $408.10 price target, and recent news highlights institutional buying and refining margin strength.
Outlook remains positive driven by earnings beats and supportive refining margins, but risks include potential diesel export policy changes and volatile energy markets. The stock's high RSI suggests near-term overbought conditions, yet fundamental improvements and strong cash flow projections for 2026 provide a solid foundation for continued investor interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
